[Role of BCG in the enlarged program of vaccination] NLM AIDSLINE Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


[Role of BCG in the enlarged program of vaccination]

Bull Soc Pathol Exot. 1991;84(5 Pt 5):843-8. Unique Identifier : AIDSLINE MED/92306282
Guerin N; Centre International de l'Enfance, Paris.

Abstract: The BCG vaccine is the most given throughout the world, and the immunization coverage is the highest: 72% in 1989 for children under one year of age. Following doubts which appeared in 1980 concerning its efficacy, many epidemiological studies confirmed the protective potency of this immunization against the severe forms of tuberculosis in children. Recent problems of tolerance arose but are now resolved by the adaptation of the vaccine concentration to the routine immunization of newborns. The world wide epidemic of AIDS and the concomitant recent increase in tuberculosis cases encourage to sustain the effort of immunization of infants. However, questions of theoretical interest have been shelved on this subject: is it reasonable to immunize HIV positive children in absence of clinical signs in countries with high prevalence? Is the vaccine effective in these special cases? Is it safe? In any case, it is the only effective and cheap way, and probably with no risk, of preventing child tuberculosis meningitis in endemic disease countries.
Keywords: Acquired Immunodeficiency Syndrome/COMPLICATIONS *BCG Vaccine English Abstract Human Infant Infant, Newborn Tuberculosis/*PREVENTION & CONTROL *Vaccination *World Health JOURNAL ARTICLEKWDacquiredimmunodeficiencysyndrome/complicationsKWDbcgvaccineenglishabstracthumaninfantinfant,newborntuberculosis/KWDprevention&controlKWDvaccinationKWDworldhealthjournalarticle
921030
M92A1011

Copyright © 1992 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .